Spark Biomedical

Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment. The company provides non-invasive bioelectric medicine designed to meet critical needs. Their current FDA-cleared neurostimulation solution is for opioid withdrawal. The technology is also evolving into neurological health, hemostasis, and pediatrics. Founded in 2018, headquartered in Houston, United States. The company has raised $31.2M in funding at the series a stage. Spark Biomedical operates in the Healthcare IT, Disease Self Management, Neurology, Wearable Technology sectors. The company focuses on Mobility Impairment, Device, Healthcare IT. Notable investors include NIH, HHS, Wave Ventures, Pathwaytocures, Wellcome Leap, Capital Factory, among others. The company is categorized under HealthTech > Healthcare IT; HealthTech > Disease Self Management.

Wearable Technology > Health and Wellness Devices > Neural > Mobility Impairment,

Disease Self Management > Neurological Disorders > Therapy > Deaddiction > Opioid Management > Device,

Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Differential Diagnosis > Electrodiagnostics > Neurology,

Neurology > Medical Devices > Therapeutic Devices > Psychiatric